Wake-Up Call: Engaging the Pharmacist in Individualizing Treatment and Optimizing Patient Outcomes in Insomnia
This Continuing Education activity is supported by an educational grant from Merck Sharp & Dohme Corp.
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
Jennifer A. Reinhold, PharmD, BCPS, BCPP
Associate Professor of Clinical Pharmacy
Department of Pharmacy Practice/
Philadelphia College of Pharmacy
University of the Sciences in Philadelphia
After completing this continuing education program, the participant will be able to:
- Outline the prevalence, pathophysiology, and consequences of insomnia.
- Review patient-specific and drug specific factors in making therapeutic decisions.
- Study the efficacy, safety, and differentiating characteristics of currently available treatment options for insomnia, particularly the newer-generation nonbenzodiazepines.
- Discuss the pharmacist’s role in assisting physicians in individualizing treatment and educating patients about insomnia, as well as nonprescription and prescription treatments.
Type of activity:
July 6, 2015
July 6, 2016
Estimated time to complete activity:
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-15-067-H01-P. The activity is available for CE credit through July 6, 2016.